Literature DB >> 23212864

Interferon alpha concentrations in blood and peritoneal fluid during treatment for hepatitis C.

C Smirne, R Minisini, M E Burlone, E Ceriani, F Corlianò, G Occhino, M Pirisi.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 23212864      PMCID： PMC3524899          DOI： 10.3747/pdi.2011.00307

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN： 0896-8608            Impact factor:   1.756


× No keyword cloud information.
  11 in total

Review 1.  Biologic effects of interferons.

Authors:  I Gresser
Journal:  J Invest Dermatol       Date:  1990-12       Impact factor: 8.551

2.  KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease.

Authors: 
Journal:  Kidney Int Suppl       Date:  2008-04       Impact factor: 10.545

3.  The preclinical development of Roferon-A.

Authors:  P W Trown; R J Wills; J J Kamm
Journal:  Cancer       Date:  1986-04-15       Impact factor: 6.860

4.  Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection.

Authors:  Tak Mao Chan; Stephen K N Ho; Colin S O Tang; Kai Chung Tse; Man Fai Lam; Kar Neng Lai; Susan Yung
Journal:  Nephrology (Carlton)       Date:  2007-02       Impact factor: 2.506

5.  Comparing survival between peritoneal dialysis and hemodialysis treatment in ESRD patients with chronic hepatitis C infection.

Authors:  Che-Yi Chou; I-Kuan Wang; Jiung-Hsiun Liu; Hsin-Hung Lin; Shu-Ming Wang; Chiu-Ching Huang
Journal:  Perit Dial Int       Date:  2010 Jan-Feb       Impact factor: 1.756

6.  Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications.

Authors:  L Rostaing; E Chatelut; J L Payen; J Izopet; C Thalamas; H Ton-That; J P Pascal; D Durand; P Canal
Journal:  J Am Soc Nephrol       Date:  1998-12       Impact factor: 10.121

Review 7.  Treatment predictors of a sustained virologic response in hepatitis B and C.

Authors:  Annika Kau; Johannes Vermehren; Christoph Sarrazin
Journal:  J Hepatol       Date:  2008-07-31       Impact factor: 25.083

Review 8.  The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment.

Authors:  Norah A Terrault; Deborah B Adey
Journal:  Clin J Am Soc Nephrol       Date:  2007-03-14       Impact factor: 8.237

9.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

10.  Pegylated interferon alpha-2a monotherapy in a peritoneal dialysis patient with chronic hepatitis C.

Authors:  Imari Mimura; Yoshitaka Ishibashi; Ryosuke Tateishi; Shinya Kaname; Toshiro Fujita
Journal:  NDT Plus       Date:  2008-06-05
View more
  1 in total

1.  Lactococcus lactis Expressing Type I Interferon From Atlantic Salmon Enhances the Innate Antiviral Immune Response In Vivo and In Vitro.

Authors:  Carlos Muñoz; Josue González-Lorca; Mick Parra; Sarita Soto; Natalia Valdes; Ana María Sandino; Rodrigo Vargas; Alex González; Mario Tello
Journal:  Front Immunol       Date:  2021-08-12       Impact factor: 7.561
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.